Oppenheimer on Kura Oncology (KURA): Tipifarnib Could Result In Sales as Early as 2019, May Reach Sales of $1.1 Billion in 2022
Tweet Send to a Friend
Oppenheimer maintains Outperform on Kura Oncology (NASDAQ: KURA) price target of $17.50.Analyst Leah Rush Cann comments "Kura Oncology had three ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
